



Ain Shams University
Faculty of Science
Biochemistry Department

Human epididymis protein 4 as a novel diagnostic ovarian cancer biomarker: comparison with cancer antigen 125 in Egyptian ovarian cancer patients

A thesis submitted in partial fulfillment of the requirements for
M.Sc. degree in Biochemistry

By

Mohamed Hassan Abd El-Magied

B.Sc. in Biochemistry (2008)

Under the supervision of

Prof. Dr. Mohamed Ragaa Mohamed

Professor of Biochemistry and Molecular Biology
Faculty of Science
Ain Shams University


Dr. Amal Fawzy Said

Assistant Professor of Clinical Pathology
National Cancer Institute
Faculty of Medicine - Cairo University

Dr. Mohamed A. M. Ali

Assistant Professor of Biochemistry
Faculty of Science
Ain Shams University

**Faculty of Science
Ain Shams University
2016**



﴿ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ ﴾

صدق الله العظيم
الآية (32) سورة البقرة

*This thesis has not been submitted
to this or any other university*

Mohamed Hassan Abd El-Magied

ACKNOWLEDGEMENT

First of all, cordial thankfulness to "*Allah*" who enabled me to finish this piece of work appropriately.

I would like to express my deep appreciation and gratitude to *Prof. Dr. Mohamed Ragaa Mohamed*, Professor of Biochemistry and Molecular Biology, Faculty of Science, Ain Shams University, for his consistent supervision, constructive suggestions and meticulous scientific help .

Words are not enough and fail to express my deep thanks and gratitude to *Dr. Mohamed Ahmed Mohamed Ali*, Assistant Prof. of Biochemistry, Faculty of Science, Ain Shams University, for his valuable encouragement, sincere guidance and wholehearted support throughout this work.

My deepest appreciation and thanks are offered to *Dr. Amal Fawzy Said*, Assistant Prof. of Clinical Pathology, National Cancer Institute, Cairo University, for her great support, helpful advice, valuable technical assistance and fruitful comments.

My deepest appreciation and thanks are offered to Pathology department, National Cancer Institute, Cairo University for their great support and helpful.

Finally, I take this opportunity to express my profound gratitude to my beloved parents, my lovely sincere wife for their moral support and patience during this work.

Mohamed Hassan Abd El-Magied

DEDICATION

**This thesis is proudly dedicated to my
beloved family
(my parents and my wife)**

**Thanks for your endless love, prayers,
sacrifices and support**

Mohamed Hassan Abd El-Magied

CONTENTS

	Page
❖ List of Abbreviations	i
❖ List of Figures	iv
❖ List of Tables	v
❖ Abstract	
❖ Introduction	1
❖ Aim of the work	6
❖ Review of literature	7
• Cancer of the ovary	7
✓ Incidence	7
✓ Risk Factors	7
✓ Types of ovarian cancer	9
✓ Cytogenetic features and oncogenesis of ovarian carcinoma	11
✓ Epithelial ovarian cancer	13
✓ Histologic subtypes of EOCs	18
I. Serous carcinoma	18
II. Endometrioid carcinoma	23
III. Clear cell carcinoma	25
IV. Mucinous carcinoma	28
V. Transitional cell carcinoma	30
✓ Grading of ovarian carcinomas	33
✓ Staging of ovarian carcinomas	34
• Treatment of ovarian cancer	37
• Diagnosis of ovarian cancer	44

• Biomarkers for ovarian cancer	47
I. Gene-based ovarian cancer biomarkers	49
1) Inherited gene mutations	49
2) Gene expression	50
II. MicroRNA-based ovarian cancer biomarkers	51
III. Serum ovarian cancer biomarkers	54
1) Cancer antigen 125	56
2) Mesothelin	60
3) Inhibin	61
4) Osteopontin	62
5) Carbohydrate antigen 72-4	63
6) Human epididymis protein 4	63
✓ Risk of ovarian malignancy algorithm	65
 ❖ Subjects and Methods	 68
• Study population and design	68
• Eligibility criteria	68
• Exclusion criteria	68
• Clinical diagnosis	69
• Biochemical investigations	70
✓ Measurement of serum CA125 levels	71
✓ Measurement of serum HE4 levels	74
✓ Calculation of the ROMA score	79
• Quantification of tissue CA125 and HE4 mRNA levels	80
I. RNA extraction	80
II. cDNA synthesis	84
III. TaqMan gene expression assay	88
• Statistical analysis	94
 ❖ Results	 96
• Demographic and clinical characteristics of	

the study cohort	96
• Serum CA125 and HE4 concentrations and ROMA score	99
• Tissue expression of CA125 and HE4 encoding genes	104
• Correlation between CA125, HE4 and ROMA	106
• Diagnostic accuracy of CA125, HE4 and ROMA	113
❖ Discussion	116
❖ Summary	134
❖ References	138
❖ Arabic summary	
❖ Arabic abstract	

LIST of ABBREVIATIONS

Abbreviation	Full name
ARID1A	: AT-rich interactive domain 1A
AUC	: area under the curve
β-ME	: β-mercaptoethanol
BRAF	: v-Raf murine sarcoma viral oncogene homolog B
BRCA1	: breast cancer type 1 susceptibility protein
BRCA2	: breast cancer type 2 susceptibility protein
CA125	: cancer antigen 125
CA72-4	: carbohydrate antigen 72-4
CCC	: clear cell carcinoma
CMIA	: chemiluminescent microparticle immunoassay
CT	: computed tomography
Ct	: cycle threshold
CTNNB1	: catenin [cadherin-associated protein] beta 1
DUSP4	: dual specificity phosphatase, 4
EC	: endometrioid carcinoma
EGFR	: epidermal growth factor receptor
EIA	: enzyme immunoassay
EOC	: epithelial ovarian cancer
FIGO	: international federation of gynecology and obstetrics
FISH	: fluorescence in situ hybridization
GAPDH	: glyceraldehyde 3-phosphate dehydrogenase
GCIG	: gynecologic cancer inter-group
HBOC	: hemoglobin-based oxygen carrier
HE4	: human epididymis protein 4
HER2/ ERBB2	: epidermal growth factor receptor 2

HGEC	: high-grade endometrioid carcinoma
HGSC	: high-grade serous carcinoma
hMLH1	: human mutL homolog 1
hMSH2	: human mutS homolog 2
HNF1	: hepatocyte nuclear factor 1
HNPCC	: hereditary non-polyposis colorectal carcinoma
HRD	: homologous repair deficiency
HRP	: horseradish peroxidase
HRR	: homologous recombination repair
IQR	: interquartile range
KRAS	: Kirsten rat sarcoma viral oncogene homolog
LGEC	: low-grade endometrioid carcinoma
LGSC	: low-grade serous carcinoma
LMP	: low malignant potential
MAb	: monoclonal antibody
MAP	: mitogen-activated protein
mBRCA	: breast cancer susceptibility gene mutation
MC	: mucinous carcinoma
MEK	: mitogen extracellular signal-regulated kinase
MMMT	: malignant mixed mesodermal tumors
MMR	: mismatch repair
MPF	: megakaryocyte potentiation factor
MR	: magnetic resonance
mTOR	: mammalian target of rapamycin
MUC16	: mucin 16
NPV	: negative predictive value
NRAS	: neuroblastoma rat sarcoma viral oncogene homolog
OPN	: osteopontin
p53	: tumor protein 53
PARP	: poly (ADP-ribose) polymerase
PAX2	: paired box gene 2

PCR	: polymerase chain reaction
PFI	: platinum-free interval
PI	: predictive index
PIK3CA	: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
PP	: predicted probability
PPP2R1A	: protein phosphatase 2, regulatory subunit A, alpha
PPV	: positive predictive value
PTEN	: phosphatase and tensin homolog
qRT-PCR	: quantitative real time polymerase chain reaction
RLUs	: relative light units
RMI	: risk of malignancy index
ROC	: receiver operating characteristic
ROMA	: risk of ovarian malignancy algorithm
RT-PCR	: reverse transcriptase polymerase chain reaction
RV	: reaction vessel
SERPINA5	: serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5
TGF- β	: transforming growth factor-beta
TKR	: tyrosine kinase receptor
TMB	: 3, 3', 5, 5'-tetramethylbenzidine
UC	: undifferentiated carcinomas
US	: ultrasound
VEGF	: vascular endothelial growth factor
WAP	: whey acidic protein
WFDC2	: whey acidic protein four-disulfide core domain 2
WHO	: world health organization
ZNF217	: zinc finger protein 217

LIST of FIGURES

Figure No.	Legend	Page
1	Prevalence of histologic types of EOC and their associated molecular genetic alterations	14
2	Oncogenesis of serous and mucinous ovarian carcinoma (a) as well as clear cell and endometrioid ovarian carcinoma (b)	17
3	Current treatment strategy in EOC	42
4	Treatment evolution of EOC based on biology and evidence	43
5	Flow chart algorithm for the diagnosis of a suspected pelvic mass	46
6	Principle of the chemiluminescent microparticle immunoassay	72
7	Principle of the sandwich enzyme immunoassay	76
8	Principle of the TaqMan gene expression assay	90
9	ROC curve analysis of serum and tissue CA125 and HE4, either alone or in combination, and of ROMA for the diagnosis of EOC by comparing benign ovarian tumor patients with EOC patients	115

LIST of TABLES

Table No.	Title	Page
1	Dualistic model of ovarian carcinogenesis	11
2	Genes linked with ovarian carcinomas	12
3	Clinical and molecular features of the five most common types of EOCs	15
4	Precursors, molecular alterations and characteristic features of the histologic subtypes of EOC	32
5	International federation of gynecology and obstetrics (FIGO) staging system for EOC	36
6	New serum biomarkers associated with ovarian cancers	55
7	Demographic and clinical characteristics of epithelial ovarian cancer patients	98
8	Serum CA125 and HE4 concentrations and ROMA score among healthy women, benign ovarian tumors patients and epithelial ovarian cancer patients	100
9	CA125 and HE4 serum concentrations and ROMA score in epithelial ovarian cancer patients according to histological type, differentiation grade and FIGO stage	103
10	Expression levels fold change of MUC16 (encoding CA125) and WFDC2 (encoding HE4) in tissue specimens of patients with benign ovarian tumors and EOC relative to healthy controls	105
11	Correlation between serum CA125 and other variables in patients with benign ovarian tumors and EOC	108

12	Correlation between serum HE4 and other variables in patients with benign ovarian tumors and EOC	109
13	Correlation between ROMA and other variables in patients with benign ovarian tumors and EOC	110
14	Correlation between tissue CA125 fold change and other variables in patients with benign ovarian tumors and EOC	111
15	Correlation between tissue HE4 fold change and other variables in patients with benign ovarian tumors and EOC	112
16	Comparison of the diagnostic performance of CA125, HE4 and ROMA in discriminating epithelial ovarian cancer from benign ovarian tumors	114

ABSTRACT

Ovarian cancer remains a major worldwide health care issue due to the lack of satisfactory diagnostic methods for early detection of the disease. Prior studies on the role of serum cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in detecting ovarian cancer present conflicting results. New tools sought to improve the accuracy of identifying malignancy are urgently needed. We aimed to evaluate the diagnostic utility of tissue CA125 and HE4 gene expression in comparison to serum CA125 and HE4 in discriminating benign from malignant pelvic masses. One-hundred Egyptian women were enrolled in this study, including 60 epithelial ovarian cancer (EOC) patients, 20 benign ovarian tumor patients as well as 20 apparently healthy women. Preoperative serum levels of CA125 and HE4 were measured by immunoassays. Tissue expression levels of genes encoding CA125 and HE4 were determined by quantitative real time polymerase chain reaction (qRT-PCR). The diagnostic performance of CA125 and HE4, measured either as mRNA or protein levels, was evaluated by receiver operating characteristic (ROC) curve. Serum CA125+serum HE4 combination and serum HE4 with area under the curve (AUC) values of 0.935 and 0.932, respectively, performed significantly better than serum CA125 alone (AUC=0.592; $P<0.001$). Tissue CA125 and HE4 (AUC=1) performed significantly better than serum CA125 ($P<0.001$), serum HE4 ($P=0.016$) and serum CA125+serum HE4 combination ($P=0.018$). Measurement of tissue CA125 and HE4 gene expression not only improves the discriminatory performance, but also broadens the range of differential diagnostic possibilities in distinguishing EOC from benign ovarian tumors.